Bayer to shell out to disgruntled Schering investors; Novartis nabs new pediatric approval for Promacta;

@FiercePharma: India's Dr. Reddy's widens strategies to move beyond basic generics. FiercePharmaAsia story | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: Mylan recalls more of the cancer meds made at Indian plants hit with FDA warning letter. Story | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Analysts: Gilead's hep C scripts keep slowing, and Q3 sales forecasts should too. More | Follow @CarlyHFierce

> Bayer agreed to fork over more money to former Schering shareholders who had sued over their proceeds from Bayer's $19.5 billion takeover in 2006. Report

> Novartis ($NVS) won FDA approval for expanded use of Promacta in children with chronic immune thrombocytopenia; the approval includes a new oral suspension formulation to make it easier for children to take the med. Release

> Doctors Without Borders is raising a red flag about intellectual property provisions in the Regional Comprehensive Economic Partnership trade agreement now under negotiation, saying the proposal would risk locking in high drug prices in developing markets. Release

> Amid debate over pharma's responsibility for disposing of unused prescription drugs, a chemist has invented a product that helps consumers do so themselves. Report

Medical Device News

@FierceMedDev: ICYMI: Roche's M&A party rages on with Kapa Biosystems deal. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: Bayer's Grants4Apps accelerator funds its second crop of digital health startups. Article | Follow @VarunSaxena2

@EmilyWFierce: Bristol-Myers, Sanofi catch a break in Plavix marketing case. FiercePharma story | Follow @EmilyWFierce

> WSJ: Debate roils over new radiation technique for breast cancer. More

> FDA approves first self-contained, mobile continuous blood glucose monitor from Dexcom. Article

Biotech News

@FierceBiotech: Analysts fret as market turbulence threatens biotech IPO market. Article | Follow @FierceBiotech

@JohnCFierce: Dumped by Roche, Constellation Pharma scrambles to join IPO queue. Report | Follow @JohnCFierce

> Rockefeller team links a promising cancer drug class to memory loss in mice. Story

> FluGen raises $12M round for universal flu vaccine. Item

> Mirna moves into unchartered waters with $81M IPO filing. More

Drug Delivery News

> India's NIPER boasts new dry crystallization method to join growing delivery market. Article

> Benitec IPO swoons amid market rout, but other drug delivery focused players still trying to debut. More

> Former Unilife employee admits that his whistleblower suit lacked merit in legal settlement. Report

> Copper naturally assembles in bio component to make stable, scalable delivery structures. Story

> Study finds novel, rectal drug delivery catheter is useful in emergency settings. Article

Pharma Manufacturing News

> China-based biotech to build manufacturing plant in Suzhou. More

> Zoetis expands Nebraska facility even as its plots 10 plant closings. Story

> GSK expanding OTC plant that had been slated for sale. Report

> Peptide maker to triple site with $18.8M project. Article

> New compounding pharmacy company backed by Bain. Item

Pharma Asia News

> China slowdown for pharma shouldn't be ignored, WSJ says. Story

> Stem cell laws in Japan a magnet for research, Nikkei says. More

> India's Dr. Reddy's widens strategies to move beyond basic generics. Report

> Samsung Bioepis on track for $1B U.S. listing next year for biosimilar powerhouse. Story

> BeiGene plans wider footprint in China with Suzhou development site. Article

And Finally... Commonly used blood pressure drugs known as beta blockers could improve survival in women suffering from ovarian cancer, a study found. Report

Suggested Articles

Former Indivior CEO Shaun Thaxter will face six months in federal prison for his role in misleading government officials on the dangers of Suboxone.

As of Friday after local time, 36 people have died in Korea after getting flu shots provided by at least seven companies, including Sanofi.

Two prominent pneumococcal vaccines from Merck and Pfizer are running low in Europe in a possible ill omen for the coming winter: report.